We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Agfa Radiology

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

MR Imaging Technique Promises More Reliable Cancer Screening and Diagnosis

By MedImaging International staff writers
Posted on 13 Jun 2016
Print article
Image: The EU-funded Horizon 2020 GlucoCEST Imaging in Neoplastic Tumours Project (Photo courtesy of GLINT 2016).
Image: The EU-funded Horizon 2020 GlucoCEST Imaging in Neoplastic Tumours Project (Photo courtesy of GLINT 2016).
A project to develop a novel advanced medical imaging technology is intended to enable earlier detection of cancer, increase survival rates, and allow for a patients’ full recovery.

The new imaging technology is intended to provide more reliable and less invasive cancer diagnosis based on a novel Magnetic Resonance Imaging (MRI) technique that could lead to game-changing diagnostic tools for cancer imaging, and enable personalized cancer treatment.

The European Union (EU)-funded GlucoCEST Imaging of Neoplastic Tumours (GLINT) project began in January 2016, and makes use of a technique called glucose-based Chemical Exchange Saturation Transfer (glucoCEST). The technique can be used to detect the massive native glucose uptake in tumors as they grow. Previously such glucose measurements had to be made using a radio-labeled glucose imaging agent, and Positron Emission Tomography (PET) imaging. The new technique does not require contrast agents and enables closer treatment monitoring.

Scientific Coordinator of GLINT, and inventor of the glucoCEST method Professor Xavier Golay, University College London (London, UK), said, “GLINT offers for the first time a possibility to bring to the clinics a much-touted new imaging technique, allowing to directly image by MRI native, non-labeled glucose the way PET does it using the expensive radio-labeled sugar analogue fluorodeoxyglucose (FDG). This represents among others a huge hope for pediatric patients and for everyone required to undergo continuous surveillance of cancer progression. It also carries the hope to reduce or at least significantly limit the costs of diagnostic cancer imaging.”

Related Links:
University College London


Print article

Channels

General/Advanced Imaging

view channel
Illustration

Machine Learning Combined with PET/CT Can Predict Heart Attack Risk

By combining information from two advanced imaging techniques with clinical data, physicians can improve their prediction of heart attacks, according to new research. When assessed together in an artificial... Read more

Imaging IT

view channel
Illustration

Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology

The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more

Industry News

view channel
Illustration

Mobile C-Arms Market to Surpass USD 1.6 Billion in 2027 Due to Growing Preference for Minimally Invasive Surgeries

The global mobile C-arms market is expected to grow at a CAGR of 5.2% from USD 1.07 billion in 2019 to USD 1.61 billion in 2027, driven primarily by an increase in the global geriatric population, rising... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.